CG Oncology’s Promising Phase 3 Trial Results Revealed

CG Oncology, Inc. ( (CGON) ) has issued an update.

On March 24, 2025, CG Oncology announced updated data from the BOND-003 Phase 3 clinical trial for cretostimogene, an investigational oncolytic immunotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer. The data revealed a 75.5% complete response rate among patients, with a median duration of response exceeding 28 months and no Grade 3 or higher treatment-related adverse events. These findings, presented at the European Association of Urology Congress, highlight cretostimogene’s potential as a breakthrough bladder cancer treatment, pending FDA approval.

More about CG Oncology, Inc.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative immunotherapies for bladder cancer, aiming to provide bladder-sparing therapeutic options that enhance the quality of life for urologic cancer patients.

YTD Price Performance: -6.63%

Average Trading Volume: 645,307

Technical Sentiment Signal: Strong Buy

Current Market Cap: $2.08B

See more data about CGON stock on TipRanks’ Stock Analysis page.